On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)’s ...

SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a ...

AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, ...

AstraZeneca PLC (NYSE:AZN)’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology ...

AstraZeneca’s AZN stock has taken a beating recently, with the company facing several pipeline setbacks in the past few months. AZN’s Recent Pipeline Setbacks In July, AstraZeneca announced the ...

Alexion, AstraZeneca's Rare Disease's Biologics License Application (BLA) for efzimfotase alfa has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month ...

The Cambridge, England-based pharmaceutical company said the recommendation, from the Committee for Medicinal Products for ...

AstraZeneca to Cut Some Direct-To-Patient US Drug Prices After Trump Demand By Maggie Fick LONDON (Reuters) -AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying ...

AstraZeneca (AZN) stock gains 0.63% after CEO purchases £7.26M in shares and EU recommends Klygefa approval for rare autoimmune disorder treatment.

AstraZeneca stock advanced in London trading on September 18, 2026 after CEO Pascal Soriot bought 60,000 shares at GBP 121.02 ...